{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:29Z","timestamp":1786985429445,"version":"build-2736575974"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004739","name":"Chinese Academy of Sciences Youth Innovation Promotion Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["BX202133"],"award-info":[{"award-number":["BX202133"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130105"],"award-info":[{"award-number":["82130105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22337003"],"award-info":[{"award-number":["22337003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82121005"],"award-info":[{"award-number":["82121005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341091"],"award-info":[{"award-number":["82341091"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22107107"],"award-info":[{"award-number":["22107107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC0864900"],"award-info":[{"award-number":["2021YFC0864900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bmcl.2025.130168","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:29:32Z","timestamp":1741638572000},"page":"130168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Research progress on critical viral protease inhibitors for coronaviruses and enteroviruses"],"prefix":"10.1016","volume":"122","author":[{"given":"Shulei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130168_bb0005","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","article-title":"Antivirals with common targets against highly pathogenic viruses","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2025.130168_bb0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2025.130168_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory cisease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2025.130168_bb0020","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.apsb.2022.07.017","article-title":"Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19","volume":"12","author":"Yi","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130168_bb0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/002.2022","article-title":"Nirmatrelvir plus rironavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination","volume":"35","author":"Reina","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.bmcl.2025.130168_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130168_bb0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/14656566.2022.2146493","article-title":"Ensitrelvir as a potential treatment for COVID-19","volume":"23","author":"McCarthy","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130168_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/infdis\/129.3.304","article-title":"An apparently new enterovirus isolated from patients with disease of the central nervous system","volume":"129","author":"Schmidt","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130168_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1423-0127-16-103","article-title":"Viral and host proteins involved in picornavirus life cycle","volume":"16","author":"Lin","year":"2009","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.bmcl.2025.130168_bb0050","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/v14102190","article-title":"Activation of host cellular signaling and mechanism of enterovirus 71 viral proteins associated with hand, foot and mouth disease","volume":"14","author":"Swain","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130168_bb0055","article-title":"Innate and adaptive immune responses against coronavirus","volume":"131","author":"Hosseini","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130168_bb0060","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2025.130168_bb0065","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jiph.2020.07.001","article-title":"Immune response in COVID-19: A review","volume":"13","author":"Chowdhury","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.bmcl.2025.130168_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12929-019-0596-8","article-title":"Interplays between enterovirus A71 and the innate immune system","volume":"26","author":"Chen","year":"2019","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.bmcl.2025.130168_bb0075","first-page":"9","article-title":"Immune evasion of enteroviruses under innate immune monitoring","volume":"2018","author":"Zhang","year":"1866","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660632","article-title":"Modulation of host immune response is an alternative strategy to combat SARS-CoV-2 pathogenesis","volume":"12","author":"Singh","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0085","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s10753-022-01656-7","article-title":"SARS-CoV-2 infection: host response, immunity, and therapeutic targets","volume":"45","author":"Shivshankar","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.bmcl.2025.130168_bb0090","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/pathogens11050522","article-title":"Surgical strikes on host defenses: role of the viral protease activity in innate immune antagonism","volume":"11","author":"Chin","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.bmcl.2025.130168_bb0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130168_bb0100","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1\u201310 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to cpG oligodeoxynucleotides","volume":"168","author":"Hartmann","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Singaling to NF-\u03baB by toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bmcl.2025.130168_bb0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-065X.2008.00727.x","article-title":"RNA recognition and signal transduction by RIG-I-like receptors","volume":"227","author":"Yoneyama","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bmcl.2025.130168_bb0115","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1128\/JVI.78.19.10636-10649.2004","article-title":"Activation of TBK1 and IKK\u03b5 kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity","volume":"78","author":"Tenoever","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0120","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/MCB.06021-11","article-title":"Contribution of a TANK-binding kinase 1\u2013interferon (IFN) regulatory factor 7 pathway to IFN-\u03b3-induced gene expression","volume":"32","author":"Farlik","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ni921","article-title":"IKK\u03b5 and TBK1 are essential components of the IRF3 signaling pathway","volume":"4","author":"Fitzgerald","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0135","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses-drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130168_bb0145","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"BBA-Mol Bsis Dis"},{"key":"10.1016\/j.bmcl.2025.130168_bb0150","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1099\/vir.0.19334-0","article-title":"The immne control and cell-to cell spread of human T-lymphotropic virus type 1","volume":"84","author":"Bangham","year":"2003","journal-title":"J Gen Viro"},{"key":"10.1016\/j.bmcl.2025.130168_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2025.130168_bb0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/diseases4030026","article-title":"Human coronaviruses: a review of virus-host interactions","volume":"4","author":"Lim","year":"2016","journal-title":"Diseases"},{"key":"10.1016\/j.bmcl.2025.130168_bb0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/22221751.2020.1870414","article-title":"SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species","volume":"10","author":"Moustaqil","year":"2021","journal-title":"Emerg Microbes Infec"},{"key":"10.1016\/j.bmcl.2025.130168_bb0170","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1189\/jlb.3RU0514-265RR","article-title":"The multifaceted nature of NLRP12","volume":"96","author":"Tuncer","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0180","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2025.130168_bb0185","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1038\/s41467-022-32922-9","article-title":"Structural and functional characterization of NEMO cleavage by SARS-CoV-2 3CLpro","volume":"13","author":"Hameedi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2025.130168_bb0190","doi-asserted-by":"crossref","first-page":"2000246","DOI":"10.1002\/pmic.202000246","article-title":"N-terminomics for the identification of in vitro substrates and cleavage site specificity of the SARS-CoV-2 main protease","volume":"21","author":"Koudelka","year":"2021","journal-title":"Proteomics"},{"key":"10.1016\/j.bmcl.2025.130168_bb0195","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130168_bb0200","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3923\/ijp.2022.1340.1352","article-title":"A spotlight on the development, pharmaceutical trends, innovations and patents of nirmatrelvir (Paxlovid\u2122)","volume":"18","author":"George","year":"2022","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0205","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","article-title":"Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir","volume":"9","author":"Chen","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0210","unstructured":"https:\/\/www.shionogi.com\/global\/en\/news\/2022\/11\/e20221122.html."},{"key":"10.1016\/j.bmcl.2025.130168_bb0215","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1021\/acs.jmedchem.2c00624","article-title":"S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2","volume":"65","author":"Tyndall","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0220","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0225","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00632-22","article-title":"Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL prptease inhibitor, in healthy adults","volume":"66","author":"Shimizu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130168_bb0230","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130168_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105450","article-title":"In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2","volume":"208","author":"Shang","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmcl.2025.130168_bb0240","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","article-title":"Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro","volume":"9","author":"Hou","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmcl.2025.130168_bb0245","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1038\/s41467-024-50931-8","article-title":"The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo","volume":"15","author":"Rhodin","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2025.130168_bb0250","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0255","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0260","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2025.130168_bb0265","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130168_bb0270","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130168_bb0275","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41564-021-00884-1","article-title":"ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity","volume":"6","author":"Liu","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0280","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41590-021-01035-8","article-title":"Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection","volume":"22","author":"Munnur","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0285","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41590-021-01056-3","article-title":"ISG15 secretion exacerbates inflammation in SARS-CoV-2 infection","volume":"22","author":"Cao","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947272","article-title":"Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner","volume":"13","author":"Ran","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0295","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acsinfecdis.1c00631","article-title":"Exploring noncovalent protease inhibitors for the treatment of severe acute respiratory syndrome and severe acute respiratory syndrome-like coronaviruses","volume":"8","author":"Freitas","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130168_bb0300","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1021\/acsinfecdis.0c00866","article-title":"The SARS-CoV-2 SSHHPS recognized by the papain-like protease","volume":"7","author":"Reynolds","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130168_bb0305","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmcl.2025.130168_bb0315","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.bmcl.2025.130168_bb0320","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2025.130168_bb0325","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmcl.2025.130168_bb0330","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2","volume":"14","author":"Sanders","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2025.130168_bb0335","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130168_bb0340","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.apsb.2024.04.011","article-title":"Discovery and charactererization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2","volume":"14","author":"Zheng","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130168_bb0345","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jmb.2011.03.007","article-title":"Crystal structure of human enterovirus 71 3C protease","volume":"408","author":"Cui","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0350","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1128\/JVI.02491-09","article-title":"The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses","volume":"84","author":"Lei","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0355","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1128\/JVI.00447-11","article-title":"Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibitors antiviral responses mediated by toll-like receptor 3","volume":"85","author":"Lei","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0360","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1128\/JVI.01855-12","article-title":"Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses","volume":"87","author":"Lei","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0365","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1128\/JVI.01425-14","article-title":"Enterovirus 71 3C inhibitors cytokine expression through cleavage of the TAK1\/TAB1\/TAB2\/TAB3 complex","volume":"88","author":"Lei","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006674","article-title":"Enterovirus 71 protease 2Apro and 3Cpro differentially inhibit the cellular endoplasmic reticulum-associated degradation (ERAD) pathway via distinct mechanisms, and enterovirus 71 hijacks ERAD component P97 to promote its replication","volume":"13","author":"Wang","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2025.130168_bb0375","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12985-021-01725-7","article-title":"3C protease of enterovirus 71 cleaves promyelocytic leukemia protein and impairs PML-NBs production","volume":"18","author":"Li","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.bmcl.2025.130168_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.806084","article-title":"Enterovirus 71 antagonizes antiviral effects of type III interferon and evades the clearance of intestinal intraepithelial lymphocytes","volume":"12","author":"Dong","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0385","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.virs.2022.04.013","article-title":"EV71 3C protease cleaves host anti-viral factor OAS3 and enhances virus replication","volume":"37","author":"Zhou","year":"2022","journal-title":"Virol Sin"},{"key":"10.1016\/j.bmcl.2025.130168_bb0390","article-title":"TRAF3IP3 is cleaved by EV71 3C protease and exhibits antiviral activity","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0395","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.virusres.2017.11.023","article-title":"Nonstructural protein 2A modulates replication and virulence of enterovirus 71","volume":"244","author":"Li","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.bmcl.2025.130168_bb0400","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1016\/j.jmb.2013.08.016","article-title":"Crystal structure of 2A proteinase from hand, foot and mouth disease virus","volume":"425","author":"Mu","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0405","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-065X.2008.00737.x","article-title":"Innate immunity to virus infection","volume":"227","author":"Takeuchi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bmcl.2025.130168_bb0410","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ni.2229","article-title":"Intrinsic antiviral immunity","volume":"13","author":"Yan","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0014-5793(00)01928-1","article-title":"Extremely efficient cleavage of EIF4G by picornaviral proteinases L and 2A in vitro","volume":"480","author":"Glaser","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmcl.2025.130168_bb0420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-5793(02)02933-2","article-title":"A thermosensitive mutant of HRV2 2A proteinase: evidence for direct cleavage of EIF4GI and EIF4GII","volume":"523","author":"Liebig","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmcl.2025.130168_bb0425","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1128\/MCB.24.4.1779-1790.2004","article-title":"Cleavage of poly(a)-binding protein by poliovirus 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff","volume":"24","author":"Kuyumcu-Martinez","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0430","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1128\/JVI.02712-13","article-title":"Enterovirus 2Apro targets MDA5 and MAVS in infected cells","volume":"88","author":"Feng","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003231","article-title":"Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses","volume":"9","author":"Wang","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2025.130168_bb0440","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1128\/JVI.06687-11","article-title":"Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1","volume":"86","author":"Lu","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0445","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.celrep.2015.05.047","article-title":"Reciprocal regulation between enterovirus 71 and the NLRP3 inflammasome","volume":"12","author":"Wang","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmcl.2025.130168_bb0450","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.3390\/v7062764","article-title":"Antiviral potential of a novel compound CW-33 against enterovirus A71 via inhibition of viral 2A protease","volume":"7","author":"Wang","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130168_bb0455","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/AAC.02274-15","article-title":"A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus","volume":"60","author":"Guo","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130168_bb0460","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/JVI.05263-11","article-title":"Ex vivo and in vivo inhibition of human rhinovirus replication by a new pseudosubstrate of viral 2A protease","volume":"86","author":"Falah","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0465","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/jac\/dks304","article-title":"Blocking human enterovirus 71 replication by targeting viral 2A protease","volume":"67","author":"Falah","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2025.130168_bb0470","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsbiomedchemau.2c00001","article-title":"Efficient strategy to design protease inhibitors: application to enterovirus 71 2A protease","volume":"2","author":"Chen","year":"2022","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.bmcl.2025.130168_bb0475","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1021\/acs.biochem.1c00414","article-title":"Pan-3C protease inhibitor rupintrivir binds SARS-CoV-2 main protease in a unique binding mode","volume":"60","author":"Lockbaum","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2025.130168_bb0480","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1021\/acs.jmedchem.0c02258","article-title":"Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2","volume":"65","author":"Dai","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0485","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130168_bb0490","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation Mpro inhibitor with potent activity against SARS-CoV-2 omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130168_bb0495","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0500","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41392-024-01758-8","article-title":"Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1","volume":"9","author":"Xie","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130168_bb0505","article-title":"An overview of viruses discovered over the last decades and drug development for the current pandemic","volume":"890","author":"Mirza","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0510","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejmech.2016.10.019","article-title":"Identification and biochemical characterization of DC07090 as a novel small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening","volume":"124","author":"Ma","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105102","article-title":"Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease","volume":"192","author":"Liu","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmcl.2025.130168_bb0520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12985-020-01430-x","article-title":"Recent advances of enterovirus 71 3Cpro targeting inhibitors","volume":"17","author":"Diamalala","year":"2020","journal-title":"Virol J"},{"key":"10.1016\/j.bmcl.2025.130168_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2024.105713","article-title":"Synthesis, evaluation, and computational chemistry of novel selenenyl sulfides as 3C protease inhibitors with strong cell-based antiviral activity","volume":"17","author":"Tang","year":"2024","journal-title":"Arab J Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0530","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13338","article-title":"Efficacy and safety of ensitrelvir for asymptomatic or mild COVID-19: an exploratory analysis of a multicenter, randomized, phase 2b\/3 clinical trial","volume":"18","author":"Ohmagari","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.bmcl.2025.130168_bb0535","first-page":"17","article-title":"High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"Protein Cell"},{"key":"10.1016\/j.bmcl.2025.130168_bb0540","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1016\/j.bmc.2008.06.015","article-title":"Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents","volume":"16","author":"Kuo","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0545","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00298-17","article-title":"Structure of the enterovirus 71 3C protease in complex with NK-1.8k and indications for the development of antienterovirus protease inhibitor","volume":"61","author":"Wang","year":"2017","journal-title":"Antimicrob Agents Ch"},{"key":"10.1016\/j.bmcl.2025.130168_bb0550","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01025-21","article-title":"4-Iminooxazolidin-2-one as a bioisostere of cyanohydrin suppresses EV71 proliferation by targeting 3Cpro","volume":"9","author":"Xu","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.bmcl.2025.130168_bb0555","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1021\/acs.jmedchem.9b00387","article-title":"Application of dually activated michael acceptor to the rational design of reversible covalent inhibitor for enterovirus 71 3C protease","volume":"62","author":"Ma","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106445","article-title":"Antiviral effects and mechanisms against EV71 of the novel 2-benzoxyl-phenylpyridine derivatives","volume":"186","author":"Wei","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bmcl.2025.130168_bb0565","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12985-018-1023-6","article-title":"Inhibition of enterovirus 71 replication and viral 3C protease by quercetin","volume":"15","author":"Yao","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.bmcl.2025.130168_bb0570","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.febslet.2009.05.008","article-title":"Individual and common inhibitors of coronavirus and picornavirus main proteases","volume":"583","author":"Kuo","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmcl.2025.130168_bb0575","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and entrerovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0580","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/v13091852","article-title":"A novel class of norovirus inhibitors targeting the viral protease with potent antiviral activity in vitro and in vivo","volume":"13","author":"Dycke","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130168_bb0585","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/v16030366","article-title":"Recent advances on targeting proteases for antiviral development","volume":"16","author":"Borges","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130168_bb0590","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/jmv.26814","article-title":"Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19","volume":"93","author":"Anirudhan","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0595","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2025.130168_bb0600","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bmcl.2025.130168_bb0605","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aag2419","article-title":"Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor","volume":"353","author":"Lei","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130168_bb0610","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1039\/b208248a","article-title":"HIV-1 protease: mechanism and drug discovery","volume":"1","author":"Brik","year":"2003","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmcl.2025.130168_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769543","article-title":"Running with scissors: evolutionary conflicts between viral proteases and the host immune system","volume":"12","author":"Tsu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0620","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60609","article-title":"Diverse viral proteases activate the NLRP1 inflammasome","volume":"10","author":"Tsu","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.bmcl.2025.130168_bb0625","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2016","article-title":"An update on enterovirus 71 infection and interferon type I response","volume":"29","author":"Rasti","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.bmcl.2025.130168_bb0630","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/JVI.02472-07","article-title":"Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon","volume":"82","author":"Narayanan","year":"2008","journal-title":"J Virol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T01:47:29Z","timestamp":1744336049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":126,"alternative-id":["S0960894X25000770"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130168","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on critical viral protease inhibitors for coronaviruses and enteroviruses","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130168"}}